1. Cholesteryl hemiazelate identified in CVD patients causes in vitro and in vivo inflammation.
- Author
-
Domingues N, Gaifem J, Matthiesen R, Saraiva DP, Bento L, Marques ARA, Soares MIL, Sampaio J, Klose C, Surma MA, Almeida MS, Rodrigues G, Gonçalves PA, Ferreira J, E Melo RG, Pedro LM, Simons K, Pinho E Melo TMVD, Cabral MG, Jacinto A, Silvestre R, Vaz W, and Vieira OV
- Subjects
- Animals, Humans, Cholesterol Esters, Monocytes, Inflammation, Esters, Zebrafish, Atherosclerosis
- Abstract
Oxidation of PUFAs in LDLs trapped in the arterial intima plays a critical role in atherosclerosis. Though there have been many studies on the atherogenicity of oxidized derivatives of PUFA-esters of cholesterol, the effects of cholesteryl hemiesters (ChEs), the oxidation end products of these esters, have not been studied. Through lipidomics analyses, we identified and quantified two ChE types in the plasma of CVD patients and identified four ChE types in human endarterectomy specimens. Cholesteryl hemiazelate (ChA), the ChE of azelaic acid (n-nonane-1,9-dioic acid), was the most prevalent ChE identified in both cases. Importantly, human monocytes, monocyte-derived macrophages, and neutrophils exhibit inflammatory features when exposed to subtoxic concentrations of ChA in vitro. ChA increases the secretion of proinflammatory cytokines such as interleukin-1β and interleukin-6 and modulates the surface-marker profile of monocytes and monocyte-derived macrophage. In vivo, when zebrafish larvae were fed with a ChA-enriched diet, they exhibited neutrophil and macrophage accumulation in the vasculature in a caspase 1- and cathepsin B-dependent manner. ChA also triggered lipid accumulation at the bifurcation sites of the vasculature of the zebrafish larvae and negatively impacted their life expectancy. We conclude that ChA behaves as an endogenous damage-associated molecular pattern with inflammatory and proatherogenic properties., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF